Rosiglitazone Maleate API

Name	Rosiglitazone maleate
Chinese name	马来酸罗格列酮
Cas Number	155141-29-0
Source	India
Qualifications	USDMF/-/-/-/-

Rosiglitazone maleate is a thiazolidinedione insulin sensitizer approved by the US FDA in May 1999. As a highly selective PPARγ agonist, it controls blood glucose levels by improving insulin sensitivity. The main mechanism of action of rosiglitazone maleate is to activate the PPARγ nuclear receptors in the tissues acted by insulin such as fat, skeletal muscle and liver, thereby regulating the transcription of insulin response genes and controlling the production, transport and utilization of blood sugar. Compared with troglitazone, rosiglitazone maleate is 100 times more active and safer than troglitazone. So far, no liver toxicity has been found in clinical trials. Rosiglitazone maleate is a national first-class drug in the field of diabetes treatment in China. It obtained two patents for compounds and synthetic methods approved by the National Patent Office in April 2000. The protection period is 20 years, so the protection period has expired. . At present, China's diabetes market has reached RMB 40 billion, of which oral drugs accounted for 56%. Rosiglitazone maleate still has considerable market space.

Hot Tags: rosiglitazone maleate api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Lapatinib Ditosylate API, Ranolazine API, Dapoxetine API, Celecoxib API, Perindopril Tert butylamine Salt API, Perindopril Arginine API

• Previous: Tibolone API
• Next: Baclofen API